{"id":556688,"date":"2026-05-30T12:30:00","date_gmt":"2026-05-30T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=556688"},"modified":"2026-05-30T13:48:55","modified_gmt":"2026-05-30T11:48:55","slug":"immune-and-targeted-therapy-options-evidence-situation-2025-2026","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/immune-and-targeted-therapy-options-evidence-situation-2025-2026\/","title":{"rendered":"Immune and targeted therapy options: Evidence situation 2025\/2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>The treatment of urothelial carcinoma has developed significantly in recent years. Modern immunotherapies, antibody-drug conjugates (ADCs) and targeted substances complement conventional chemotherapies and increasingly enable individualized treatment strategies. New data from 2025 and 2026 show that combination therapies, maintenance concepts and biomarker-based approaches in particular are gaining in importance. In addition, modern therapy planning is benefiting from more precise diagnostics.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fimmune-and-targeted-therapy-options-evidence-situation-2025-2026%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>The treatment of urothelial carcinoma has developed significantly in recent years. Modern immunotherapies, antibody-drug conjugates (ADCs) and targeted substances complement conventional chemotherapies and increasingly enable individualized treatment strategies. New data&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fimmune-and-targeted-therapy-options-evidence-situation-2025-2026%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":556693,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Urothelial carcinoma ","footnotes":""},"category":[11548,11508,11370,11503,11490],"tags":[92714,92713,92704,92674,92681,18787,92711,92690,92679,92699,92707,92709,92677,92716,92692,67218,92712,92715,92673,92664,78139,92705,92694,92717,92702,92696,15767,92668,92700,89932,92683,92689,92685,92666,11767,92687,49919,92718,17595,92710,92670],"powerkit_post_featured":[],"class_list":["post-556688","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-education","category-oncology","category-studies","category-urology","tag-adc-therapy-2","tag-antibodies-active-substance-conjugates","tag-avelumab-maintenance","tag-biomarker-based-therapy","tag-bl-b01d1","tag-bladder-cancer-en","tag-carboplatin-combination","tag-chaplain-meier-pfs-os","tag-disitamab-vedotin","tag-durvalumab-combination","tag-enfortumab-vedotin","tag-evp","tag-fgfr-directed-therapy","tag-fgfr3-mutation","tag-first-line-urothelial-therapy","tag-functional-imaging","tag-gemcitabine-cisplatin","tag-her2-expression","tag-her2-directed-therapy","tag-immune-checkpoint-inhibitors-3","tag-interdisciplinary-tumor-boards","tag-javelin-bladder100","tag-metastatic-urothelial-carcinoma","tag-nectin-4-expression","tag-nectin-4-pet","tag-neoadjuvant-chemotherapy","tag-pembrolizumab-en","tag-pet-ct-capacities-switzerland","tag-pet-ct-prognosis","tag-platinum-based-chemotherapy","tag-propensity-score-analysis","tag-real-world-evidence-evp","tag-second-line-urothelial-therapy","tag-swiss-healthcare-system-oncology","tag-targeted-therapy","tag-toripalimab","tag-tumor-biology","tag-urinary-tract-carcinoma","tag-urothelial-carcinoma","tag-urothelial-immunotherapy","tag-urothelial-sequential-therapy","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-14 08:24:12","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":556684,"slug":"options-therapeutiques-immunologiques-et-ciblees-niveau-de-preuve-2025-2026","post_title":"Options th\u00e9rapeutiques immunologiques et cibl\u00e9es : Niveau de preuve 2025\/2026","href":"https:\/\/medizinonline.com\/fr\/options-therapeutiques-immunologiques-et-ciblees-niveau-de-preuve-2025-2026\/"},"it_IT":{"locale":"it_IT","id":556681,"slug":"opzioni-di-terapia-immunitaria-e-mirata-situazione-delle-evidenze-2025-2026","post_title":"Opzioni di terapia immunitaria e mirata: Situazione delle evidenze 2025\/2026","href":"https:\/\/medizinonline.com\/it\/opzioni-di-terapia-immunitaria-e-mirata-situazione-delle-evidenze-2025-2026\/"},"pt_PT":{"locale":"pt_PT","id":556685,"slug":"opcoes-de-terapia-imune-e-direcionada-situacao-da-evidencia-2025-2026","post_title":"Op\u00e7\u00f5es de terapia imune e direcionada: Situa\u00e7\u00e3o da evid\u00eancia 2025\/2026","href":"https:\/\/medizinonline.com\/pt-pt\/opcoes-de-terapia-imune-e-direcionada-situacao-da-evidencia-2025-2026\/"},"es_ES":{"locale":"es_ES","id":556678,"slug":"opciones-de-terapia-inmunologica-y-dirigida-situacion-de-las-pruebas-2025-2026","post_title":"Opciones de terapia inmunol\u00f3gica y dirigida: Situaci\u00f3n de las pruebas 2025\/2026","href":"https:\/\/medizinonline.com\/es\/opciones-de-terapia-inmunologica-y-dirigida-situacion-de-las-pruebas-2025-2026\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/556688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=556688"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/556688\/revisions"}],"predecessor-version":[{"id":556697,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/556688\/revisions\/556697"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/556693"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=556688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=556688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=556688"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=556688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}